nach oben

Erschienen in:

01.03.2010 | Leading Article

Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

Rationale and Current Evidence

verfasst von: Prof. Dr Richard Dodel, Frauke Neff, Carmen Noelker, Refik Pul, Yansheng Du, Michael Bacher, Wolfgang Oertel

Erschienen in: Drugs | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Current treatment options for Alzheimer’s disease (AD) exert only a shortlived effect on disease symptoms. Active and passive immunotherapy have both been shown to be effective in clearing plaques, removing β-amyloid (Aβ) and improving behaviour in animal models of AD. Although the first active immunization trial in humans was discontinued because of severe adverse effects, several new approaches are currently being investigated in clinical trials. Recently, commercially available intravenous immunoglobulins (IVIG) have been used in small pilot trials for the treatment of patients with AD, based on the hypothesis that IVIG contains naturally occurring auto-antibodies (nAbs-Aβ) that specifically recognize and block the toxic effects of Ab. Furthermore, these nAbs-Aβ are reduced in AD patients compared with healthy controls, supporting the notion of replacement with IVIG. Beyond the occurrence of nAbs-Aβ, evidence for several other mechanisms associated with IVIG in AD has been reported in preclinical experiments and clinical studies. In 2009, a phase III clinical trial involving more than 360 AD patients was initiated and may provide conclusive evidence for the effect of IVIG as a treatment option for AD in 2011. In this article, we review the current knowledge and scientific rationale for using IVIG in patients with AD and other neurodegenerative disorders.

Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006; 253 Suppl. 5: V18–24PubMedCrossRef

Gold R, Stangel M, Dalakas MC. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 2007; 3(1): 36–44PubMedCrossRef

Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol 2008; 15(9): 893–908PubMedCrossRef

Neff F, Wei X, Nolker C, et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008; 7(6): 501–7PubMedCrossRef

Mandelkow E, von Bergen M, Biernat J, et al. Structural principles of tau and the paired helical filaments of Alzheimer’s disease. Brain Pathol 2007; 17(1): 83–90PubMedCrossRef

Hardy J. Has the amyloid cascade hypothesis for Alzheimer’s disease been proved? Curr Alzheimer Res 2006; 3(1): 71–3PubMedCrossRef

Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007; 69(16): 1622–34PubMedCrossRef

Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008; 31: 175–93PubMedCrossRef

Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400(6740): 173–7PubMedCrossRef

10.

Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000; 408(6815): 982–5PubMedCrossRef

11.

Roskam S, Neff F, Schwarting R, et al. APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. Neurosci Biobehav Rev 2010; 34(4): 487–99PubMedCrossRef

12.

Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005; 64(1): 94–101PubMedCrossRef

13.

Schenk D. Amyloid-beta immunotherapy for Alzheimer’s disease: the end of the beginning. Nat Rev Neurosci 2002; 3(10): 824–8PubMedCrossRef

14.

Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553–62PubMedCrossRef

15.

Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008; 372(9634): 216–23PubMedCrossRef

16.

Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003; 38(4): 547–54PubMedCrossRef

17.

Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6(8): 916–9PubMedCrossRef

18.

Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/-knock-out mice. J Neurosci 2003; 23(24): 8532–8PubMed

19.

Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9(4): 448–52PubMedCrossRef

20.

Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001; 7(3): 369–72PubMedCrossRef

21.

Taguchi H, Planque S, Nishiyama Y, et al. Autoantibody-catalyzed hydrolysis of amyloid beta peptide. J Biol Chem 2008; 283(8): 4714–22PubMedCrossRef

22.

DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001; 98(15): 8850–5PubMedCrossRef

23.

Frenkel D, Maron R, Burt DS, et al. Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 2005; 115(9): 2423–33PubMedCrossRef

24.

Solomon B. Antibody-mediated immunotherapy for Alzheimer’s disease. Curr Opin Investig Drugs 2007; 8(7): 519–24PubMed

25.

Morgan C, Colombres M, Nunez MT, et al. Structure and function of amyloid in Alzheimer’s disease. Prog Neuro-biol 2004; 74(6): 323–49CrossRef

26.

Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008; 14(8): 837–42PubMedCrossRef

27.

Sarsoza F, Saing T, Kayed R, et al. A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol 2009; 118(4): 505–17PubMedCrossRef

28.

Moretto N, Bolchi A, Rivetti C, et al. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J Biol Chem 2007; 282(15): 11436–45PubMedCrossRef

29.

Petkova AT, Ishii Y, Balbach JJ, et al. A structural model for Alzheimer’s beta-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 2002; 99(26): 16742–7PubMedCrossRef

30.

Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298(5597): 1379PubMedCrossRef

31.

Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat Neurosci 2002; 5(5): 452–7PubMed

32.

O'Nuallain B, Acero L, Williams AD, et al. Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry 2008; 47(47): 12254–6PubMedCrossRef

33.

Mohajeri MH, Gaugler MN, Martinez J, et al. Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. Neurodegener Dis 2004; 1(4–5): 160–7PubMedCrossRef

34.

Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004; 24(27): 6144–51PubMedCrossRef

35.

Kountouris D. Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type. J Neural Transm 2000; 107(5): 18

36.

Dodel R, Du Y, Depboylu C, et al. Intravenous Immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2004; 75: 1472–4PubMedCrossRef

37.

Relkin NR, Szabo P, Adamiak B, et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009; 30(11): 1328–36CrossRef

38.

Relkin N, Tsakanikas DI, Adamiak B, et al. A double blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer’s disease [abstract]. Neurology 2008; 70(11): A393

39.

A phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild to moderate Alzheimer’s disease [Clinical-Trials.gov identifier NCT00818662]. US National Institutes of Health, ClinicalTrials.gov, 2009 [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 10]

40.

Study of Octagam 10% on the treatment of mild to moderate Alzheimer’s patients [ClinicalTrials.gov identifier NCT00812565]. US National Institutes of Health, ClinicalTrials.gov, 2009 [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Feb 10]

41.

Du Y, Dodel R, Hampel H, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 2001; 57(5): 801–5PubMedCrossRef

42.

Dodel R, Hampel H, Depboylu C, et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer’s disease. Ann Neurol 2002; 52(2): 253–6PubMedCrossRef

43.

Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002; 37(7): 943–8PubMedCrossRef

44.

Shoenfeld Y, Gershwin ME, Meroni PL. Autoantibodies. Amsterdam: Elsevier, 2007

45.

Fillit H, Hess G, Hill J, et al. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009; 73(3): 180–5PubMedCrossRef

46.

Misra N, Bayry J, Ephrem A, et al. Intravenous immunoglobulin in neurological disorders: a mechanistic perspective. J Neurol 2005; 252 Suppl. 1: I1–6PubMedCrossRef

47.

Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol 2008; 255 Suppl. 3: 3–6PubMedCrossRef

48.

Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747–55PubMedCrossRef

49.

Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008; 26: 513–33PubMedCrossRef

50.

Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8(1): 34–47PubMedCrossRef

51.

Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19: 275–90PubMedCrossRef

52.

Bruhns P, Samuelsson A, Pollard JW, et al. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 2003; 18(4): 573–81PubMedCrossRef

53.

Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291(5503): 484–6PubMedCrossRef

54.

Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98(4): 1095–9PubMedCrossRef

55.

Siragam V, Crow AR, Brinc D, et al. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 2006; 12(6): 688–92PubMedCrossRef

56.

Bazin R, Lemieux R, Tremblay T. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135(1): 97–100PubMedCrossRef

57.

Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 2004; 113(9): 1328–33PubMed

58.

Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313(5787): 670–3PubMedCrossRef

59.

Anthony RM, Wermeling F, Karlsson MC, et al. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105(50): 19571–8PubMedCrossRef

60.

Konrad S, Baumann U, Schmidt RE, et al. Intravenous immunoglobulin (IVIG)-mediated neutralisation of C5a: a direct mechanism of IVIG in the maintenance of a high Fc gammaRIIB to Fc gammaRIII expression ratio on macrophages. Br J Haematol 2006; 134(3): 345–7PubMedCrossRef

61.

Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992; 62 (1 Pt 2): S82–6PubMedCrossRef

62.

Mollnes TE, Hogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48(3): 312–7PubMedCrossRef

63.

Lutz HU, Stammler P, Jelezarova E, et al. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996; 88(1): 184–93PubMed

64.

Basta M, Van Goor F, Luccioli S, et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9(4): 431–8PubMedCrossRef

65.

Rissmann A, Pieper S, Adams I, et al. Increased blood plasma concentrations of TGF-beta1 and TGF-beta2 after treatment with intravenous immunoglobulins in childhood autoimmune diseases. Pediatr Allergy Immunol 2009; 20(3): 261–5PubMedCrossRef

66.

Stangel M, Schumacher HC, Ruprecht K, et al. Immunoglobulins for intravenous use inhibit TNF alpha cytotoxicity in vitro. Immunol Invest 1997; 26(5-7): 569–78PubMedCrossRef

67.

Wu KH, Wu WM, Lu MY, et al. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr Allergy Immunol 2006; 17(1): 60–8PubMedCrossRef

68.

Ghio M, Contini P, Negrini S, et al. sHLA-I contaminating molecules as novel mechanism of ex vivo/in vitro transcriptional and posttranscriptional modulation of transforming growth factor-beta in CD8+ T lymphocytes and neutrophils after intravenous immunoglobulin treatment. Transfusion. Epub 2009 Nov 9

69.

Kekow J, Reinhold D, Pap T, et al. Intravenous immunoglobulins and transforming growth factor beta. Lancet 1998; 351(9097): 184–5PubMedCrossRef

70.

Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007; 26(1): 67–78PubMedCrossRef

71.

Gaskin F, Finley J, Fang Q, et al. Human antibodies reactive with beta-amyloid protein in Alzheimer’s disease. J Exp Med 1993; 177(4): 1181–6PubMedCrossRef

72.

Gaskin F, Kingsley BS, Fu SM. Autoantibodies to neuro-fibrillary tangles and brain tissue in Alzheimer’s disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med 1987; 165(1): 245–50

73.

Du Y, Wei X, Dodel R, et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003; 126 (Pt 9): 1935–9PubMedCrossRef

74.

Xu S, Gaskin F. Increased incidence of anti-beta-amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer’s disease. Mech Ageing Dev 1997; 94(1–3): 213–22PubMedCrossRef

75.

Geylis V, Kourilov V, Meiner Z, et al. Human monoclonal antibodies against amyloid-beta from healthy adults. Neurobiol Aging 2005; 26(5): 597–606PubMedCrossRef

76.

Istrin G, Bosis E, Solomon B. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006; 84(2): 434–43PubMedCrossRef

77.

Schaffer C, Blanché-Ganter E. Qualität polyvalenter Immunglobuline. Krankenhauspharmazie 1998; 19: 280–6

78.

Pul R, Nguyen D, Schmitz U, et al. Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/IgA-enriched preparation. Clin Neuropharmacol 2002; 25(5): 254–9PubMedCrossRef

79.

Kellner A, Matschke J, Bernreuther C, et al. Autoantibodies against beta-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann Neurol 2009; 65(1): 24–31PubMedCrossRef

80.

Tampellini D, Magrane J, Takahashi RH, et al. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem 2007; 282(26): 18895–906PubMedCrossRef

81.

Moir RD, Tseitlin KA, Soscia S, et al. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer’s disease patients. J Biol Chem 2005; 280(17): 17458–63PubMedCrossRef

82.

Song MS, Mook-Jung I, Lee HJ, et al. Serum anti-amyloid-beta antibodies and Alzheimer’s disease in elderly Korean patients. J Int Med Res 2007; 35(3): 301–6PubMed

83.

Sohn JH, So JO, Hong HJ, et al. Identification of auto-antibody against beta-amyloid peptide in the serum of elderly. Front Biosci 2009; 14: 3879–83PubMedCrossRef

84.

Jianping L, Zhibing Y, Wei Q, et al. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis Assoc Disord 2006; 20(3): 127–32PubMedCrossRef

85.

Brettschneider S, Morgenthaler NG, Teipel SJ, et al. Decreased serum amyloid beta(1–42) autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1–42) peptide. Biol Psychiatry 2005; 57(7): 813–6PubMedCrossRef

86.

Hansson SF, Andreasson U, Wall M, et al. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer’s disease patients. J Alzheimers Dis 2009; 16(2): 389–97PubMed

87.

Nath A, Hall E, Tuzova M, et al. Autoantibodies to amyloid beta-peptide (Abeta) are increased in Alzheimer’s disease patients and Abeta antibodies can enhance Abeta neurotoxicity: implications for disease pathogenesis and vaccine development. Neuromolec Med 2003; 3(1): 29–39CrossRef

88.

Gruden MA, Davudova TB, Malisauskas M, et al. Autoimmune responses to amyloid structures of Abeta(25–35) peptide and human lysozyme in the serum of patients with progressive Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 18(2): 165–71PubMedCrossRef

89.

Mruthinti S, Buccafusco JJ, Hill WD, et al. Autoimmunity in Alzheimer’s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 2004; 25(8): 1023–32PubMedCrossRef

90.

Hyman BT, Smith C, Buldyrev I, et al. Autoantibodies to amyloid-beta and Alzheimer’s disease. Ann Neurol 2001; 49(6): 808–10PubMedCrossRef

91.

Baril L, Nicolas L, Croisile B, et al. Immune response to Abeta-peptides in peripheral blood from patients with Alzheimer’s disease and control subjects. Neurosci Lett 2004; 355(3): 226–30PubMedCrossRef

92.

Weber A, Engelmaier A, Teschner H, et al. Intravenous immunoglobulin (IVIG) Gammagard Liquid contains anti-RAGE IGG and SLRP. ICAD Abstract 2009; P3: 43

93.

Dalakas MC, Späth PJ. Intravenous immunoglobulins in the third millennium. New York: Parthenon Publishing Group, 2004

94.

Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59 (12 Suppl. 6): S13–21PubMedCrossRef

95.

Quan Y, Moller T, Weinstein JR. Regulation of Fcgamma receptors and immunoglobulin G-mediated phagocytosis in mouse microglia. Neurosci Lett 2009; 464(1): 29–33PubMedCrossRef

96.

Sewell WA, North ME, Cambronero R, et al. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999; 116(3): 509–15PubMedCrossRef

97.

World Health Organization. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting. WHO Bulletin 1982; 60: 43–7

98.

International patient organisation for primary immunodeficiencies. IVIG preparations currently available. 2009 [online]. Available from URL: http://www.ipopi.org/data/ [Accessed 2010 Feb 10]

99.

Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol 2006; 6(4): 592–9PubMedCrossRef

100.

Martin TD. IGIV: contents, properties, and methods of industrial production-evolving closer to a more physiologic product. Int Immunopharmacol 2006; 6(4): 517–22PubMedCrossRef

101.

Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62 (16 Suppl. 3): S5–11PubMedCrossRef

102.

Relkin NR, Szabo P, Rotondi M, et al. Antibodies in the dimer fraction of IVIG have the capacity to bind beta amyloid. ICAD Abstract 2009: 43

103.

Safavi A. Comparison of several human immunoglobulin products for anti-Aβ 1–42 titer [abstract]. Alzheimer’s Dementia 2006; 2 (3 Suppl. 1): S591CrossRef

104.

Balakrishnan K, Andrei-Selmer L, Selmer T, et al. Comparison of intravenous immunoglobulins for naturally occurring antibodies against β-amyloid. J Alzheimers Dis. In press

105.

Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol 2006; 6(4): 535–42PubMedCrossRef

106.

Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007; 6(4): 257–9PubMedCrossRef

107.

Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007; 38(1-3): 122–32PubMedCrossRef

108.

Stangel M, Kiefer R, Pette M, et al. Side effects of intravenous immunoglobulins in neurological autoimmune disorders—a prospective study. J Neurol 2003; 250(7): 818–21PubMedCrossRef

109.

Brannagan 3rd TH, Nagle KJ, Lange DJ, et al. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47(3): 674–7PubMedCrossRef

110.

Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol 2003; 50(3): 172–5PubMedCrossRef

111.

Papachroni KK, Ninkina N, Papapanagiotou A, et al. Autoantibodies to alpha-synuclein in inherited Parkinson’s disease. J Neurochem 2007; 101(3): 749–56PubMedCrossRef

112.

Shankle WR. Longitudinal measure of IVIG treatment effect in patients with Alzheimer’s and Lewy body disease. ICAD Abstract 2009; P3: 43

113.

Rosenmann H, Meiner Z, Geylis V, et al. Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer’s disease and healthy subjects. Neurosci Lett 2006; 410(2): 90–3PubMedCrossRef

114.

Wei X, He Y, Tan J, et al. Human anti-prion protein antibodies block A117V PrProtein fibril formation and prevent A117V prion protein peptide-induced neurotoxicity. Eur Psychiatry 2008; 23: S39–SCrossRef

115.

Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat Clin Pract Neurol 2007; 3(3): 120–1PubMedCrossRef

116.

Boulis A, Goold S, Ubel PA. Responding to the immunoglobulin shortage: a case study. J Health Polit Policy Law 2002; 27(6): 977–99PubMedCrossRef

Titel: Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease
Rationale and Current Evidence
verfasst von: Prof. Dr Richard Dodel
Frauke Neff
Carmen Noelker
Refik Pul
Yansheng Du
Michael Bacher
Wolfgang Oertel
Publikationsdatum: 01.03.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 5/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11533070-000000000-00000

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

Rationale and Current Evidence

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Advances in the Pharmacological Management of Huntington’s Disease

B Cell-Targeted Therapies for Systemic Lupus Erythematosus

Raltegravir

Nomegestrol Acetate

Histrelin

Seizure Outcomes Following the Use of Generic versus Brand-Name Antiepileptic Drugs